A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help neutralize and eliminate diseas | Immunology ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

An indigenously developed CAR T-cell gene therapy has achieved a 73% response rate for certain blood cancers in India. The ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

A new study published in The Lancet Haematology journal says that an indigenously developed gene therapy for certain blood ...